ClinicalTrials.gg
Status unknownNCT05050487Updated Apr 28, 2022

Pericapsular Nerve Group Block Versus Lumber Erector Spinae Plane Block for Pain Management After Total Hip Arthroplasty

An interventional study of PENG block and lumbar erector spinae plane block in Post Operative Pain, Chronic, sponsored by Assiut University. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-28.

Sponsored by Assiut University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Pain is a major problem that has to be dealt with in case of hip fracture, as it presents an obstacle for examination, positioning for receiving neuroaxial anesthesia and postoperative mobility and physiotherapy. With the introduction of ultrasound in regional anesthesia and peripheral nerve blocks, regional analgesia float to the surface as a substitute for opioids with less side effects Lumbar erector spinae plane block has emerged as a reliable analgesic option for primary total hip arthroplasty (THA). In 2018, a new block was described, termed pericapsular nerve group block or PENG block, that selectively targets the articular branches of the femoral and obturator nerves while sparing their motor components

Read the detailed description

Pain is a major problem that has to be dealt with in case of hip fracture, as it presents an obstacle for examination, positioning for receiving neuroaxial anesthesia and postoperative mobility and physiotherapy. With the introduction of ultrasound in regional anesthesia and peripheral nerve blocks, regional analgesia float to the surface as a substitute for opioids with less side effects Lumbar erector spinae plane block has emerged as a reliable analgesic option for primary total hip arthroplasty (THA). In 2018, a new block was described, termed pericapsular nerve group block or PENG block, that selectively targets the articular branches of the femoral and obturator nerves while sparing their motor components The pericapsular nerve group (PENG) block is an ultrasound-guided approach first de-scribed by Giron-Arango et al. for the blockade of the articular branches of the femoral (FN), obturator (ON) and accessory obturator (AON) nerve that provide sensory innervation to the an¬terior hip capsule. It has been developed as an alternative regional anesthesia technique for the management of acute pain after hip fractures, but its applications are expanding.

Currently, the PENG block has been used to control and reduce pain in hip-related procedures.

There are reports of PENG blocks used as surgical anesthetic techniques for hip arthroplasty (in combination with local anesthetic and intravenous analgesics) or hip arthroscopy (in combination with lateral femoral cutaneous nerve [LFCN] block). There is a report of a PENG block used as analgesic technique for sickle cell disease vaso-occlusive crisis and a PENG radiofrequency ablation for osteoarthritis analgesia. There are also reports about the use of a PENG block for non-hip related interventions, such as leg vein ligation and stripping, medial thigh surgery, prevention of adductor muscle spasm during transurethral resection of bladder and below-knee amputation in association with popliteal sciatic nerve block.These latter cases further extended the application of the PENG block beyond the hip-related area.

So far, most of the reports describe preoperative or postoperative single-shot blocks, while there are only few case reports of continuous PENG blocks.

Due to the novelty of this technique, there are still ongoing debates about the best injection point as well as the best anesthetic concentration and the total volume to be injected.

Defined in the last decade, erector spinae plane block (ESPB) is one of the more frequently used interfacial plans, and it has been the most discussed block among the recently defined techniques. Lumbar ESPB administered at lumbar levels is relatively novel and is a new horizon for regional anesthesia and pain practice.(14)

02

Conditions studied

  • Post Operative Pain, Chronic

Browse trials for

03

In context

Pain, Postoperative

5,227 studies on the registry are indexed under Pain, Postoperative; 1,154 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 4,457 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ASA grade 1\&2 \&3
  2. Adult patients (Age >18 yrs)
  3. Eligible patients were aged 18 years or older, were admitted for hip arthroplasty (THA or HA) for femoral neck fracture, and had undergone a preoperative RA technique (PENG block or lumbar erector spinae plane block)

Exclusion criteria

Exclusion Criteria:

  1. Patients with chronic pain before surgery (taking opioids)
  2. Patients with multiple trauma
  3. Patients who could not assess pain reliably (dementia)
  4. Patients who in anticoagulation
  5. Patient refused
  6. Infection at the side of injection
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    treatment

    patient will recieve pericapsular nerve group block

    Procedure: PENG block

  • Experimental
    treatement

    patient will receive lumbar erector spinae plane block

    Procedure: lumbar erector spinae plane block

Interventions

  • ProcedurePENG block

    The PENG block is performed under US guid¬ance, . The pa¬tient is placed in the supine position a curvilinear low-fre¬quency ultrasound probe (2-5 MHz) is initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe approximately 30-45 degrees . . The needle, usually a 22-G80-mm echogenic device, is inserted from lateral to medial with an in-plane approach to place the tip in the plane between the psoas tendon anteriorly and the pu¬bic ramus posteriorly . After needle insertion and following negative aspiration, the local anesthetic is injected . The volume used of 20 ml of(L-bupivacaine; concentration 0,25% ) . This fascial plane appeared to continue in the hip pericapsular plane.

    Also known as: pericapsular nerve group block

  • Procedurelumbar erector spinae plane block

    The lumbar erector spinae block is performed under US guid¬ance, after adequate skin disinfection The patient is placed in the lateral decubitus position according to the selected site of surgical intervention. The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.25%). All LA was administered to this location between the transverse process and the erector spinae muscle.

    Also known as: ESPB

06

What researchers measure

Primary outcomes

  1. Duration of analgesia

    the time passed from block to the patient's first analgesic request in hours

    Time frame: 24 hour

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05050487
Lead sponsor
Assiut University
Responsible party
Abdeltwab Younis Tamam (assisstant lecturer of anesthesia and intensive care, Assiut University) — Principal investigator
First posted
Sep 20, 2021
Start date
Jun 30, 2022 (estimated)
Primary completion
Oct 30, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Apr 28, 2022

Study contacts

Abdeltwab Younis
Contact
abdeltwabyonis91@gmail.com
01098518513

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion